Letter to FDA re Draft Guidance on Considerations for Use of AI

American Society of Hematology. (2025).
Letter to FDA re Draft Guidance on Considerations for Use of AI.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/letter-to-fda-re-draft-guidance-on-considerations-for-use-of-ai.

American Society of Hematology.
"Letter to FDA re Draft Guidance on Considerations for Use of AI." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/letter-to-fda-re-draft-guidance-on-considerations-for-use-of-ai
(label-accessed May 21, 2025).

"American Society of Hematology."
Letter to FDA re Draft Guidance on Considerations for Use of AI, 21 May. 2025 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/letter-to-fda-re-draft-guidance-on-considerations-for-use-of-ai.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero